Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus Erlotinib in Refractory NSCLC
NCT00801385Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Sep 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in non-small cell lung cancer (NSCLC), sponsored by Yonsei University. Status: unknown.
02
Drugs
sorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00801385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00801385.